论文部分内容阅读
重组人粒细胞集落刺激因子（ｒｈＧ－ＣＳＦ，ｆｉｌｇｒａｓｔｉｍ）有促进粒系造血干细胞增殖分化及增强成熟粒细胞功能的作用。本文报告异基因骨髓移植后接受Ｇ－ＣＳＦ治疗的患者共２０例。Ｇ－ＣＳＦ自骨髓移植后ｄ６开始应用，用量为１０ｍｇ·ｋｇ￣（－１）·ｄ￣（－１），连用２０ｄ至连续３ｄ粒细胞＞１．０×１０￣９／ｌ或白细胞＞２．０×１０￣９／ｌ为止。结果表明，粒细胞升至＞０．．５×１０￣９／ｌ及＞１．０×１０￣９／ｌ的平均天数试用组为１３．８及１５．４ｄ；对照组为２１．８及２８．４ｄ（Ｐ＜０．００１）。白细胞升至＞１．０×１０￣９／ｌ及２．０×１０￣９／ｌ的平均天数，试用组为１４．５及１６．３ｄ；对照组为２３．６及３２．３ｄ（Ｐ＜０．００１）。但两组血小板升至＞２０×１０￣９／Ｌ的时间及骨髓移植后输血小板的次数两组无显著差异。骨髓移４植后５ｗｋ内发烧的平均天数试用组每人１．２ｄ；对照组每人４．５ｄ（Ｐ＜０．０１）。作者认为，异基因骨髓移植后应用Ｇ－ＣＳＦ治疗有明显促进粒细胞恢复的作用。且可降低骨髓移植早期的感染率。
Recombinant human granulocyte colony-stimulating factor (rhG-CSF, filgrastim) can promote the proliferation and differentiation of myeloid hematopoietic stem cells and enhance the function of mature granulocytes. This article reports a total of 20 patients who received G-CSF after allogeneic bone marrow transplantation. G-CSF began to be applied on day 6 after bone marrow transplantation, and the dosage was 10 mg · kg -1 (d -1) for 20 days, continuous 3d granulocytes> 1.0 × 10 -9 / l or leukocyte> 2 .0 × 10 ~ 9 / l so far. The results showed that granulocytes rose to> 0. . The average days of 5 × 10 ~ 9 / l and> 1.0 × 10 ~ 9 / l were 13.8 and 15.4 days in the trial group and 21.8 and 28.4 days in the control group (P <0.001). White blood cells rose to> 1.0 × 10 ~ 9 / l and 2.0 × 10 ~ 9 / l average days, the trial group was 14.5 and 16.3d; control group was 23.6 and 32.3d (P <0.001). However, there was no significant difference between the two groups when the number of platelets rose to> 20 × 10 ~ 9 / L and the number of transfusion platelets after bone marrow transplantation. The mean number of days with fever in 5 weeks after transplantation of bone marrow was 1.2 days in the trial group and 4.5 days in the control group (P <0.01). The authors believe that the application of G-CSF after allogeneic bone marrow transplantation significantly promote the recovery of granulocytes. And can reduce the early infection rate of bone marrow transplantation.